Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Vandenbroucke K et al. – This report details a new therapeutic approach for treatment of chronic colitis, involving in situ secretion of anti–mTNF Nanobodies by orally administered L. lactis bacteria. Therapeutic application of these engineered bacteria could eventually lead to more effective and safer management of IBD in humans.

   

Related Articles

Medical Management of Ulcerative Colitis
Digestive Diseases, 11/09/09    Relevance Score: 91%

Oxidized Form Of A Common Vitamin May Bring Relief For Ulcerative Colitis
ScienceDaily, 10/02/09    Relevance Score: 89%

CD4+ T Cells and Lactobacillus casei Control Relapsing Colitis Mediated by CD8+ T Cells
Journal of Immunology, 10/22/09    Relevance Score: 88%

Ischemic Colitis After Endovascular Aortoiliac Aneurysm Repair
Archives of Surgery, 10/20/09    Relevance Score: 88%

Microscopic colitis: a review for the surgical endoscopist
Canadian Journal of Surgery, 10/16/09    Relevance Score: 88%

Today in Allergy/Immunology...keeping you current

Effects of endogenous glucocorticoids on allergic inflammation and TH1/TH2 balance in airway allergic disease
Annals of Allergy, Asthma, and Immunology, 12/18/09

Temperature modulated histamine-itch in lesional and nonlesional skin in atopic eczema a combined psychophysical and neuroimaging study
Allergy, 12/18/09

Anti-TNF-[alpha] therapy with infliximab in spondyloarthritides
Expert Review of Clinical Immunology, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address